Role of Imaging in the Staging and Response Assessment of Lymphoma : Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
BARRINGTON, SALLY F.; MIKKHAEEL, N. GEORGE; KOSTAKOGLU, LALEet al.
Assessment of Lymphoma; Lymphoma; Staging of Lymphomas; Role of Imaging; PET-CT
Abstract :
[en] This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for 18F FDG-avid lymphomas in clinical practice and late-phase trials.
Disciplines :
Radiology, nuclear medicine & imaging Hematology Oncology
Author, co-author :
BARRINGTON, SALLY F.; KING'S COLLEGE - LONDON - UNITED KINGDOM
MIKKHAEEL, N. GEORGE; GUY'S AND THOMAS'S NATIONAL HEALTH SERVICE FOUNDATION TRUST - LONDON - UNITED KINGDOM
KOSTAKOGLU, LALE; MOUNT SINAI MEDICAL CENTER
MEIGNAN, MICHEL; CENTRE UNIVERSITAIRE HOSPITALIER HENRI MONDOR - PARIS - FRANCE
HUTCHINGS, MARTIN; RIGSHOSPITALET - COPENHAGEN UNIVERSITY HOSPITAL - DENMARK
Role of Imaging in the Staging and Response Assessment of Lymphoma : Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Publication date :
11 August 2014
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
American Society of Clinical Oncology, Alexandria, United States - Virginia
A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
Solal-Céligny P, Roy P, Colombat P, et al.: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
Hoster E, Dreyling M, Klapper W., et al.: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111: 558-565, 2008
Younes A: Early-stage Hodgkin's lymphoma: In pursuit of perfection. J Clin Oncol 30:895-896, 2012
Rosenwald A, Wright G, Chan W.C., et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
Cheson BD: Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844-1854, 2011
Juweid ME, Stroobants S, Hoekstra O.S., et al.: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007
Cheson BD, Pfistner B, Juweid M.E., et al.: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
Hutchings M, Loft A, Hansen M., et al.: Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91:482-489, 2006
Rigacci L, Vitolo U, Nassi L., et al.: Positron emission tomography in the staging of patients with Hodgkin's lymphoma: A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann He-matol 86:897-903, 2007
Raanani P, Shasha Y, Perry C., et al.: Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 17:117-122, 2006
Elstrom R, Leonard JP, Coleman M, et al.: Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19: 1770-1773, 2008
Pelosi E, Pregno P, Penna D., et al.: Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma [in English, Italian]. Radiol Med 113: 578-590, 2008
Karam M, Novak L, Cyriac J., et al.: Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107: 175-183, 2006
Janikova A, Bolcak K, Pavlik T., et al.: Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma? Clin Lymphoma Myeloma 8:287-293, 2008
Wirth A, Foo M, Seymour J.F., et al.: Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys 71:213-219, 2008
Le Dortz L, De Guibert S, Bayat S, et al.: Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 37:2307-2314, 2010
Luminari S, Biasoli I, Arcaini L., et al.: The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 24:2108-2112, 2013
Hutchings M, Mikhaeel NG, Fields P.A., et al.: Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160-1168, 2005
Hutchings M, Loft A, Hansen M., et al.: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
Gallamini A, Rigacci L, Merli F., et al.: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91:475-481, 2006
Gallamini A, Hutchings M, Rigacci L., et al.: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
Cerci JJ, Pracchia LF, Linardi C.C., et al.: 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 51:1337-1343, 2010
Zinzani PL, Rigacci L, Stefoni V., et al.: Early interim 18F-FDG PET in Hodgkin's lymphoma: Evaluation on 304 patients. Eur J Nucl Med Mol Imaging 39:4-12, 2012
Biggi A, Gallamini A, Chauvie S., et al.: International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med 54:683-690, 2013
Cerci JJ, Trindade E, Pracchia L.F., et al.: Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol 28:1415-1421, 2010
Engert A, Haverkamp H, Kobe C., et al.: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379: 1791-1799, 2012
Yang DH, Min JJ, Song H.C., et al.: Prognostic significance of interim (18)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 47:1312-1318, 2011
Zinzani PL, Gandolfi L, Broccoli A., et al.: Midtreat-ment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 117: 1010-1018, 2011
Pregno P, Chiappella A, Bello M., et al.: Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 119: 2066-2073, 2012
Safar V, Dupuis J, Itti E., et al.: Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus ritux-imab. J Clin Oncol 30:184-190, 2012
Micallef IN, Maurer MJ, Wiseman G.A., et al.: Epratuzumab with rituximab, cyclophospha-mide, doxorubicin, vincristine, and prednisonechem-otherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 118:4053-4061, 2011
Trotman J, Fournier M, Lamy T., et al.: Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 29:3194-3200, 2011
Dupuis J, Berriolo-Riedinger A, Julian A., et al.: Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol 30:4317-4322, 2012
Hutchings M, Barrington SF: PET/CT for therapy response assessment in lymphoma. J Nucl Med 50:21S-30S, 2009 (suppl 1)
Kostakoglu L, Gallamini A: Interim 18F-FDG PET in Hodgkin lymphoma: Would PET-adapted clinical trials lead to a paradigm shift? J Nucl Med 54:1082-1093, 2013
Shankar LK, Hoffman JM, Bacharach S, et al.: Consensus recommendations for the use of F-18-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med 47:1059-1066, 2006
Scheuermann JS, Saffer JR, Karp J.S., et al.: Qualification of PET scanners for use in multicenter cancer clinical trials: The American College of Radiology Imaging Network experience. J Nucl Med 50:1187-1193, 2009
Boellaard R, O'Doherty MJ, Weber WA, et al.: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging 37:181-200, 2010
Barrington SF, MacKewn JE, Schleyer P, et al.: Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol 22:739-745, 2011
Boellaard R, Oyen WJ, Hoekstra C.J., et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 35:2320-2333, 2008
Barrington SF, Qian W, Somer E.J., et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol maging 37:1824-1833, 2010
Meignan M, Gallamini A, Haioun C: Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 50:1257-1260, 2009
Radford J, Barrington S, Counsell N., et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a "negative" PET scan after 3 cycles ABVD: Results of the UK NCRI RAPID trial Blood 120, 2012 (abstr 547)
Johnson P, Federico M, Fossa A., et al Responses and chemotherapy dose adjustment determined by PET-CT imaging: First results from the International Response Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL) study. Hematol Oncol 31:96-150, 2013 (abstr 126)
Gallamini A, Rossi A, Patti C., et al.: Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients with a positive FDG-PET scan after two ABVD courses: First interim analysis of the GITIL/FIL HD0607 clinical trial. Blood 120, 2012 (abstr 550)
Southwest Oncology Group: Fluorodeoxyglu-cose F 18-PET/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV Hodgkin lymphoma: 02/12 update. http://clinicaltrials.gov/ct2/show/NCT00822120
International Extranodal Lymphoma Study Group (IELSG): A randomized, open-label two-arm phase III comparative study assessing the role of nvolved mediastinal radiotherapy after rituximab containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma: 03/2013. http://clinicaltrials.gov/ct2/show/NCT01599559
Millennium Pharmaceuticals: A randomized, open-label, phase 3 trial of A + AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin lymphoma: 08/13 update. http://clinicaltrials.gov/ct2/show/NCT01712490
Dührsen U, Hüttmann A, Jockel K.H., et al. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas: The PETAL trial. Leuk Lymphoma 50:1757-1760, 2009
Young H, Baum R, Cremerius U., et al.: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations-European Organisation for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773-1782, 1999
Bourguet P, Blanc-Vincent MP, Boneu A., et al.: Summary of the standards, options and recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET scanning) in oncology. Br J Cancer 89:S84-S91, 2003 (suppl 1)
Coleman RE, Delbeke D, Guiberteau M.J., et al.: Concurrent PET/CT with an integrated imaging system: Intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med 46:1225-1239, 2005
Boellaard R: Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11S-20S, 2009 (suppl 1)
Haioun C, Itti E, Rahmouni A., et al.: F-18 fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 106:1376-1381, 2005
Markova J, Kobe C, Skopalova M., et al.: FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 20:1270-1274, 2009
Mikhaeel NG, Hutchings M, Fields P.A., et al.: FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in highgrade non-Hodgkin lymphoma. Ann Oncol 16:1514-1523, 2005
Nols N, Mounier N, Bouazza S., et al.: Quantitative and qualitative analysis of metabolic response at interim PET-scan combined with IPI is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma 55:773-780, 2014
Spaepen K, Stroobants S, Dupont P., et al.: Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1356-1363, 2002
Barnes JA, LaCasce AS, Zukotynski K, et al.: End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol 22:910-915, 2011
Spaepen K, Stroobants S, Dupont P., et al.: Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419, 2001
Elstrom R, Guan L, Baker G., et al.: Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875-3876, 2003
Tsukamoto N, Kojima M, Hasegawa M., et al.: The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scin-tigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652-659, 2007
Weiler-Sagie M, Bushelev O, Epelbaum R., et al.: (18)F-FDG avidity in lymphoma readdressed: A study of 766 patients. J Nucl Med 51:25-30, 2010
Bodet-Milin C, Touzeau C, Leux C., et al.: Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: A retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 37:1633-1642, 2010
Feeney J, Horwitz S, Gönen M, et al.: Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol 195:333-340, 2010
Cahu X, Bodet-Milin C, Brissot E., et al.: 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: A study from the GOELAMS group. Ann Oncol 22:705-711, 2011
Barrington SF, O'Doherty MJ: Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 30:S117-S127, 2003 (suppl 1)
Cook GJ, Wegner EA, Fogelman I: Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 34:122-133, 2004
El-Galaly TC, d'Amore F, Mylam KJ, et al.: Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30: 4508-4514, 2012
Moulin-Romsee G, Hindié E, Cuenca X, et al.: (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 37:1095-1105, 2010
Richardson SE, Sudak J, Warbey V., et al.: Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era. Leuk Lymphoma 53:381-385, 2012
Schaefer NG, Strobel K, Taverna C., et al.: Bone involvement in patients with lymphoma: The role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 34:60-67, 2007
Berthet L, Cochet A, Kanoun S., et al.: In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 54:1244-1250, 2013
Mittal BR, Manohar K, Malhotra P., et al.: Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging? Leuk Lymphoma 52:2111-2116, 2011
Ngeow JY, Quek RH, Ng D.C., et al.: High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol 20: 1543-1547, 2009
Pelosi E, Penna D, Douroukas A., et al.: Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: Results from a large multicentre study. Q J Nucl Med Mol Imaging 55:469-475, 2011
Cheson BD: Hodgkin lymphoma: Protecting the victims of our success. J Clin Oncol 30:4456-4457, 2012
Khan AB, Barrington SF, Mikhaeel N.G., et al.: PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 122:61-67, 2013
Carr R, Barrington SF, Madan B, et al.: Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91:3340-3346, 1998
Paone G, Itti E, Haioun C., et al.: Bone marrow involvement in diffuse large B-cell lymphoma: Correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging 36:745-750, 2009
Chen YK, Yeh CL, Tsui C.C., et al.: F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: A meta-analysis. Clin Nucl Med 36:553-559, 2011
O'Doherty MJ, Barrington SF, Campbell M, et al.: PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 38:1575-1583, 1997
Barrington SF, Mikhaeel NG: When should FDG-PET be used in the modern management of lymphoma? Br J Haematol 164:315-328, 2014
Lin C, Itti E, Haioun C., et al.: Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626-1632, 2007
Itti E, Lin C, Dupuis J., et al.: Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 50:527-533, 2009
Quarles van Ufford H, Hoekstra O, de Haas M, et al.: On the added value of baseline FDG-PET in malignant lymphoma. Mol Imaging Biol 12:225-232, 2010
Meignan M, Itti E, Bardet S., et al.: Development and application of a real-time on-line blinded ndependent central review of interim PET scans to determine treatment allocation in lymphoma trials J Clin Oncol 27:2739-2741, 2009
Mikhaeel NG, Timothy AR, O'Doherty MJ, et al.: 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma 39:543-553, 2000
Mikhaeel NG: Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma Where are we now? Leuk Lymphoma 50:1931-1936, 2009
Fuertes S, Setoain X, Lopez-Guillermo A, et al.: Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma. Eur J Nucl Med Mol maging 40:496-504, 2013
Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodg-kin's lymphoma patients treated with interim response-adapted strategy: Comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 38 1064-1071, 2011
Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: Comparison between Deauville criteria and SSUVmax. Eur J Nucl Med Mol Imaging 40 1312-1320, 2013
Martelli M, Ceriani L, Zucca E., et al. [18F]Fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol [epub ahead of print on May 5, 2014]
Fondazione Italiana Linfomi: Amulticenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage follicular lymphoma: FIL FOLL12-Update 07/13. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract-number:2012-003170-60
Spectrum Pharmaceuticals: Study of zevalin versus observation in patients at least 60 yrs old with newly diagnosed diffuse large B-cell lymphoma in PET-negative complete remission after R-CHOP or R-CHOP-like therapy: 11/13 update. http://www.clinicaltrials.gov/ct2/show/NCT01510184
Lymphoma Academic Research Organisation: Study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non Hodgkin's lymphoma CD 20+: Update 10/13. http://www.clinicaltrials.gov/ct2/show/NCT01285765
Furth C, Amthauer H, Hautzel H., et al.: Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma-results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 22:1198-1203, 2011
Mamot C, Klingbiel D, Renner C., et al.: Final results of a prospective evaluation of the predictive value of interim PET in patients with DLBCL under R-CHOP-14 (SAKK 38/07). Hematol Oncol 31:100-101, 2013 (suppl 1; abst 15)
Itti E MM, Berriolo-Riedinger A, Biggi A, et al.: An international validation study of the prognostic role of interim FDG PET/CT in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 40:1312-1320, 2013
de Langen AJ, Vincent A, Velasquez L.M., et al.: Repeatability of 18F-FDG uptake measurements in tumors: A metaanalysis. J Nucl Med 53:701-708, 2012
Wahl RL, Jacene H, Kasamon Y., et al.: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S-150S, 2009 (suppl 1)
Roy FN, Beaulieu S, Boucher L., et al.: Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med 50:178-183, 2009
Lister TA, Crowther D, Sutcliffe S.B., et al.: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998
Bangerter M, Moog F, Buchmann I., et al.: Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9:1117-1122, 1998
Partridge S, Timothy A, O'Doherty MJ, et al.: 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Ann Oncol 11:1273-1279, 2000
Jerusalem G, Beguin Y, Fassotte M.F., et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 86:266-273, 2001
Weihrauch MR, Re D, Bischoff S., et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 81:20-25, 2002
Munker R, Glass J, Griffeth L.K., et al.: Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 15:1699-1704, 2004
Naumann R, Beuthien-Baumann B, Reiss A., et al.: Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 90:620-625, 2004
Buchmann I, Reinhardt M, Elsner K., et al.: 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma: A bicenter trial. Cancer 91:889-899, 2001
Wirth A, Seymour JF, Hicks R.J., et al.: Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 112:262-268, 2002
Schöder H, Noy A, Gönen M, et al.: Intensity of [18F]fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23:4643-4651, 2005
Watanabe R, Tomita N, Takeuchi K., et al.: SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma 51:279-283, 2010
Schaefer NG, Hany TF, Taverna C, et al.: Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging-Do we need contrast-enhanced CT? Radiology 232:823-829, 2004
Gollub MJ, Hong R, Sarasohn D.M., et al.: Limitations of CT during PET/CT. J Nucl Med 48: 1583-1591, 2007
Pinilla I, Gómez-León N, Del Campo-Del Val L, et al.: Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma. Q J Nucl Med Mol Imaging 55:567-575, 2011
Chalaye J, Luciani A, Enache C., et al.: Clinical impact of contrast-enhanced computed tomography combined with low-dose 18F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management. Leuk Lymphoma [epub ahead of print on April 3, 2014]
Hoskin PJ, Díez P, Williams M., et al.: Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) 25:49-58, 2013
Vriens D, Visser EP, de Geus-Oei LF, et al.: Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging 37:1408-1425, 2010
Berthelsen AK, Holm S, Loft A., et al.: PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 32:1167-1175, 2005
Eichenauer DA, Engert A, Dreyling M: Hodg-kin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22:vi55-vi58, 2011 (suppl 6)
Pfreundschuh M, Kuhnt E, Trümper L, et al.: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12:1013-1022, 2011
Miller TP: The limits of limited stage lymphoma. J Clin Oncol 22:2982-2984, 2004
Coiffier B, Lepage E, Briere J., et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
Federico M, Bellei M, Marcheselli L., et al.: Follicular Lymphoma International Prognostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 27:4555-4562, 2009
Yan J, Zhao B, Wang L., et al.: Marker-controlled watershed for lymphoma segmentation in sequential CT images. Med Phys 33:2452-2460, 2006
Yan J, Zhuang TG, Zhao B, et al.: Lymph node segmentation from CT images using fast marching method. Comput Med Imaging Graph 28:33-38, 2004
Manohar K, Mittal BR, Bhattacharya A, et al. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma Nucl Med Commun 33:974-981, 2012
Kim TM, Paeng JC, Chun I.K., et al.: Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer 119:1195-1202, 2013
Kostakoglu L, Goldsmith SJ, Leonard J.P., et al.: FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107:2678-2687, 2006
Terasawa T, Lau J, Bardet S., et al.: Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodg-kin's lymphoma and diffuse large B-cell lymphoma A systematic review. J Clin Oncol 27:1906-1914, 2009
Hagberg H, Gisselbrecht C: Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cel lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: An update of the CORAL study. Ann Oncol 17:iv31-iv32, 2006 (suppl 4)
Cashen AF, Dehdashti F, Luo J., et al.: (18)F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: Poor predictive value of International Harmonization Project interpretation J Nucl Med 52:386-392, 2011
Yoo C, Lee DH, Kim J.E., et al.: Limited role of nterim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 90 797-802, 2011
Yang DH, Ahn JS, Byun B.H., et al.: Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol 92:471-479, 2013
Sehn LH, Donaldson J, Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005
Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al.: SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118:37-43, 2011
Boellaard R: Need for standardization of 18F-FDG PET/CT for treatment response assessments J Nucl Med 52:93S-100S, 2011 (suppl 2)
Kostakoglu L, Schöder H, Johnson J.L., et al. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: Would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma 53:2143-2150, 2012
Song MK, Chung JS, Shin H.J., et al.: Clinical significance of metabolic tumor volume by PET/CT n stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 91:697-703, 2012
UK Clinical Research Network: Blinded evaluation of prognostic value of FDG-PET after 2 cycles of chemotherapy in diffuse large B-cell non-Hodgkin's lymphoma: Update 09/12. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=1760
Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al.: F-18-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: A systematic review. Haematologica 91:522-529, 2006
Mikhaeel NG, Timothy AR, Hain S.F., et al. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 11:147-150, 2000 (suppl 1)
Dupuis J, Itti E, Rahmouni A., et al.: Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: Integrating (18)fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 20:503-507, 2009
Reinhardt MJ, Herkel C, Altehoefer C., et al. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: When do we really need FDG-PET? Ann Oncol 16:1524-1529, 2005
Magagnoli M, Marzo K, Balzarotti M., et al. Dimension of residual CT scan mass in Hodgkin's lymphoma (HL) is a negative prognostic factor in patients with PET negative after chemo +/- radiotherapy Blood 118, 2011 (abstr 93)
Dabaja BS, Phan J, Mawlawi O., et al.: Clinical mplications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma 54:2631-2638, 2013
Savage KJ, Connors JM, Klasa R.J., et al.: The use of FDG-PET to guide consolidative radiotherapy n patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. J Clin Oncol 29:512s, 2011 (suppl; abstr 8034)
Barrington SF, Mikhaeel NG: Imaging follicular lymphoma using positron emission tomography with [18F]fluorodeoxyglucose: To what purpose? J Clin Oncol 30:4285-4287, 2012
Svoboda J, Andreadis C, Elstrom R., et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 38:211-216, 2006
Schot BW, Zijlstra JM, Sluiter W.J., et al.: Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109:486-491, 2007
Jabbour E, Hosing C, Ayers G., et al.: Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109: 2481-2489, 2007
Moskowitz AJ, Yahalom J, Kewalramani T., et al.: Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116:4934-4937, 2010
Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 17:1646-1652, 2011
Sucak GT, Ozkurt ZN, Suyani E, et al.: Early post-transplantation positron emission tomography n patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol 90:1329-1336, 2011
Terasawa T, Dahabreh IJ, Nihashi T: Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before highdose chemotherapy for lymphoma: A systematic review and meta-analysis. Oncologist 15:750-759, 2010
Thomson KJ, Kayani I, Ardeshna K., et al.: A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin lymphoma. Leukemia 27:1419-1422, 2013
Moskowitz CH, Matasar MJ, Zelenetz A.D., et al.: Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119: 1665-1670, 2012
Hutchings M: Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: Time to shift gears for PET-positive patients? Leuk Lymphoma 52:1615-1616, 2011
Dunleavy K, Pittaluga S, Maeda L.S., et al.: Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368: 1408-1416, 2013
Zinzani PL: PET in T-cell lymphoma. Curr Hematol Malig Rep 6:241-244, 2011
Otero HJ, Jagannathan JP, Prevedello L.M., et al.: CT and PET/CT findings of T-cell lymphoma. AJR Am J Roentgenol 193:349-358, 2009
Casulo C, Schöder H, Feeney J., et al.: FDG-PET in the staging and prognosis of T cell lymphoma. Leuk Lymphoma 54:2163-2167, 2013
